Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Nov 1;87(18):1878-1883.
doi: 10.1212/WNL.0000000000003158. Epub 2016 Aug 31.

Trial of early noninvasive ventilation for ALS: A pilot placebo-controlled study

Teresa L Jacobs  1 , Devin L Brown  2 , Jonggyu Baek  2 , Erin M Migda  2 , Timothy Funckes  2 , Kirsten L Gruis  2
Affiliations
Randomized Controlled Trial

Trial of early noninvasive ventilation for ALS: A pilot placebo-controlled study

Teresa L Jacobs et al. Neurology. .

Abstract

Objective: To evaluate the use and tolerability of noninvasive positive pressure ventilation (NIV) in patients with amyotrophic lateral sclerosis (ALS) early in their disease by comparing active NIV and sham NIV in patients not yet eligible for NIV use as recommended by practice guidelines.

Methods: This was a single-center, prospective, double-blind, randomized, placebo (sham)-controlled pilot trial. Patients with ALS were randomized to receive either sham NIV or active NIV and underwent active surveillance approximately every 3 months until they reached a forced vital capacity (FVC) <50% or required NIV for clinical symptom management.

Results: In total, 54 participants were randomized. The mean NIV use was 2.0 hours (95% confidence interval [CI] 1.1-3.0) per day in the sham NIV treatment group and 3.3 hours (CI 2.0-4.6) per day in the active NIV group, which did not differ by treatment group (p = 0.347). The majority of sham NIV participants (88%) and active NIV participants (73%) reported only mild or no problem with NIV use. Difference of change in FVC through the treatment period by group (0.44 per month) favored active NIV (p = 0.049). Survival and changes in maximal inspiratory or expiratory pressure did not differ between treatment groups.

Conclusions: The efficacy of early NIV in ALS should be tested in randomized, placebo-controlled trials. The trial is registered on clinicaltrials.gov (NCT00580593).

Classification of evidence: This study provides Class II evidence that for patients with ALS, adherence with NIV and sham NIV are similar.

PubMed Disclaimer

References

    1. Miller RG, Jackson CE, Kasarskis EJ, et al. . Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1218–1226. - PMC - PubMed
    1. Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation: a consensus conference report. Chest 1999;116:521–534. - PubMed
    1. Aboussouan LS, Mireles-Cabodevila E. Respiratory support in patients with amyotrophic lateral sclerosis. Respir Care 2013;58:1555–1558. - PubMed
    1. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis: subcommittee on motor neuron diseases/amyotrophic lateral sclerosis of the World Federation of Neurology Research Group on neuromuscular diseases and the El Escorial “clinical limits of amyotrophic lateral sclerosis” workshop contributors. J Neurol Sci 1994(124 suppl):96–107. - PubMed
    1. Mehta S, Hill NS. Noninvasive ventilation. Am J Respir Crit Care Med 2001;163:540–577. - PubMed

Publication types

Associated data